See how ctDNA can be used
to monitor cancer.7
Use Guardant tests to personalize critical treatment decisions
for improved patient outcomes.1
Match patients with advanced-stage cancer to the right treatment at the right time through comprehensive molecular profiling.2
CGP, comprehensive genomic profiling; ctDNA, circulating tumor DNA; DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; ER+, estrogen receptor–positive; ESR1, estrogen receptor 1; mBC, metastatic breast cancer; mCRC, metastatic colorectal cancer; OS, overall survival; RNA, ribonucleic acid
*Liquid and tissue testing may be initiated at the same time, but sample processing does not occur concurrently.
†Patients who have a negative Guardant360® Liquid CDx test result for an indicated companion diagnostic marker should be reflexed to tissue biopsy testing using an FDA-approved tumor tissue test, if feasible.
References: 1. Aggarwal C, Marmarelis ME, Hwang WT, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer. JCO Precis Oncol. 2023;7:e2300191. doi:10.1200/PO.23.00191 2. Matsubara J, Mukai K, Kondo T, et al. First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open. 2023;6(7):e2323336. doi:10.1001/jamanetworkopen.2023.23336 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer. V.5.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 26, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Cui W, Milner-Watts C, O'Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 5. Clemens K, Bucheit L, Forbes S, Alshurafa H, Das A, Eltoukhy H. Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers. Cancer Res. 2026;86(7 suppl):6512. doi:10.1158/1538-7445.AM2026-6512 6. Tung L, Valouev A, Odegaard J, et al. Fusion epigenotyping using cell-free DNA methylation improves detection of actionable ALK fusions in non-small cell lung cancer. Abstract presented at: American Association for Cancer Research Annual Meeting; April 20, 2026; San Diego, CA. Abstract 1409. 7. Martins I, Ribeiro IP, Jorge J, et al. Liquid biopsies: applications for cancer diagnosis and monitoring. Genes (Basel). 2021;12(3):349. doi:10.3390/genes12030349 8. Burstein HJ, DeMichele A, Somerfield MR, et al. Testing for ESR1 mutations to guide therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41(18):3423-3425. doi:10.1200/JCO.23.00638 9. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol.2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. 10. Bauchner H, Fontanarosa PB, Flanagin A. Conflicts of interests, authors, and journals: new challenges for a persistent problem. JAMA. 2018;320(22):2315-2318. doi:10.1001/jama.2018.17593 11. Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9):1415-1421. doi:10.1038/s41591-019-0561-9 12. Mayrhofer M, De Laere B, Whitington T, et al. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements, and clonal hematopoiesis. Genome Med. 2018;10(1):85. doi:10.1186/s13073-018-0595-5